학술논문

VIM: the results of a phase 1/2 trial of bortezomib, idarubicin and melphalan in relapsed or refractory multiple myeloma
Document Type
Journal
Source
BRITISH JOURNAL OF HAEMATOLOGY; APR 2020, 189 p118-p118, 1p. Supplement: 1
Subject
Language
English
ISSN
13652141